Stockscreener 앱 받기
325.62
3.61%
-12.45
전일 마감가:
$338.07
열려 있는:
$349
하루 거래량:
277.49K
Relative Volume:
0.67
시가총액:
$9.07B
수익:
$7.46M
순이익/손실:
$-303.27M
주가수익비율:
-24.18
EPS:
-13.4668
순현금흐름:
$-249.12M
1주 성능:
+2.21%
1개월 성능:
+6.25%
6개월 성능:
+93.71%
1년 성능:
+755.50%
1일 변동 폭
$317.92
$353.00
1주일 범위
$310.00
$353.00
52주 변동 폭
$35.21
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
325.56 | 9.42B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
426.08 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
713.81 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.82 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.33 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.36 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-02 | 개시 | Wells Fargo | Equal Weight |
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance - Stock Titan
A seizure drug cut monthly seizures 77% as Praxis nears 2 FDA calls - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
Praxis earnings up next as biotech nears commercial transformation - Investing.com
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795 - Moomoo
FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares - Stock Titan
Price-Driven Insight from (PRAX) for Rule-Based Strategy - Stock Traders Daily
Praxis gives 21 new employees stock awards tied to hiring - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Inc expected to post a loss of $3.57 a shareEarnings Preview - TradingView
Praxis Precision Medicines (PRAX.US) will release its earnings report before the market opens on May 7. - Moomoo
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference - The Manila Times
Praxis maps out two investor events in May, starting with Q1 results - Stock Titan
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge? - Yahoo Finance
A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns - Yahoo Finance
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $567 - Moomoo
Analysts Project Growth for Praxis Precision Medicines Biotech Stock - HarianBasis.co
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Insider Monkey
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines stock drops 2.74% as positive Phase 3 Essential Tremor data shared at AANAM - Traders Union
How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates - simplywall.st
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology - Insider Monkey
M&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision gains as lead asset accepted for FDA review - MSN
(PRAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Praxis Precision Medicines (PRAX) Projected to Post Earnings on Friday - MarketBeat
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks - Insider Monkey
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX (Praxis Precision Medicines Inc.) shares rise nearly 7 percent despite wider than expected Q4 2025 per share loss.Stability Report - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Upside Stocks to Buy According to Analysts - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $567 - Moomoo
Praxis Precision Medicines (PRAX) Is Up 8.1% After FDA Accepts Ulixacaltamide NDA for Essential Tremor - simplywall.st
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $545 - 富途牛牛
Massachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) - MSN
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
5.78%
0.81%
자본화:
|
볼륨(24시간):